Biomarker ID 2464 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2464 |
| Biomarker | EGR3, MFAP3, EST, MMP9, PDCD4, EST, FLJ37853, ARHE, MAD2L1, NMNAT2, FLJ22016, SND1, MIDORI, FLJ36229, MGST2, CTPS2, OASL, HK2, EEF2, Taxilin, NT5C, CLNS1A, UNC5B, TSC, TNFSF6, KIAA1691, S100A10, ATP6V1D, ASB4, AGR2, KIAA0205, JJAZ1, LOC285859, KIAA0157, PPA2, eIF3k, SGKL, BLMH, ERG-1, BRCA2, PPP2R2A |
| Biomarker Name/Symbol (given in Publication) | 63 genes- signature (EGR3, MFAP3, EST, MMP9, PDCD4, EST, FLJ37853, ARHE, MAD2L1, NMNAT2, FLJ22016, SND1, MIDORI, FLJ36229, MGST2, CTPS2, OASL, HK2, EEF2, Taxilin, NT5C, CLNS1A, UNC5B, TSC, TNFSF6, KIAA1691, S100A10, ATP6V1D, ASB4, AGR2, KIAA0205, JJAZ1, LOC285859, KIAA0157, PPA2, eIF3k, SGKL, BLMH, ERG-1, BRCA2, PPP2R2A, IGKC, ENPEP, BIRC4, FLJ10244, LOC283167, GLS, GPR125, KDELR3, ERO1L, LENG8, DJ1042K10.2, IFNB1, SMAP-1, SET07, POLR2H, PVRL2, EST, ALDH9A1, CALM1, NR1D2, TMPO, COQ3) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | 63-genes signature can predict the response of patients with advanced HCC and major portal vein tumor thrombi to combination chemotherapy with 5-fluorouracil and interferon-alpha |
| Experimental Condition | treatment responder v/s non-responders |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed (14 Upregulated and 49 Downregulated) in treatment responder v/s non-responders |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 15447987 |
| Type of Biomarker | Predictive |
| Pathway | |
| Cohort | 20 patients: 15 of the 20 patients were treated with three cycles of the combination chemotherapy with 5-fluorouracil and interferon-alpha. The remaining five patients received only one or two cycles of 5-FU |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | 85% |
| AUC | NA |
| Disease | HCC patients treated with combination chemotherapy with 5-fluorouracil and interferon-alpha. The remaining five patients received only one or two cycles of 5-FU |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |